Kenvue (NYSE:KVUE) Updates FY 2025 Earnings Guidance

Kenvue (NYSE:KVUE) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.440-1.469 for the period, compared to the consensus earnings per share estimate of 1.250. The company issued revenue guidance of $15.3 billion-$15.6 billion, compared to the consensus revenue estimate of $15.9 billion.

Kenvue Price Performance

Shares of KVUE stock traded up $0.30 on Friday, reaching $20.10. 10,853,820 shares of the company were exchanged, compared to its average volume of 12,488,188. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a market cap of $38.53 billion, a price-to-earnings ratio of 36.55, a P/E/G ratio of 2.05 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business has a 50-day moving average price of $21.61 and a 200 day moving average price of $21.93.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Equities research analysts forecast that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 4.08%. Kenvue’s dividend payout ratio is presently 149.09%.

Analysts Set New Price Targets

Several analysts recently issued reports on KVUE shares. JPMorgan Chase & Co. upped their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Canaccord Genuity Group dropped their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday. UBS Group dropped their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.